XML 105 R42.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Compensation - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Feb. 28, 2022
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
May 19, 2022
May 09, 2022
Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Remaining expense     $ 3,600,000            
Life to date expense $ 1,600,000                
Stock-based compensation expense related to options granted   $ 5,051,000   $ 6,750,000 $ 14,292,000 $ 13,741,000      
Income tax benefits recognized         0        
Unamortized employee stock-based compensation   23,600,000     $ 23,600,000        
Unamortized employee stock-based compensation expected to recognized over remaining estimated vesting period         2 years 6 months 29 days        
Unvested PSOs cancelled 275,000                
Novosteo                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Unamortized employee stock-based compensation   1,200,000     $ 1,200,000        
Unamortized employee stock-based compensation expected to recognized over remaining estimated vesting period         3 years 8 months 23 days        
Number of shares, Cancelled and converted             0.0911    
Performance Stock Options                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Number of Shares, Surrendered (400,000)                
Stock-based compensation expense related to options granted   0     $ 2,044,000,000        
Unamortized employee stock-based compensation   0     $ 0        
Restricted stock units                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Number of Shares, Surrendered         (226,538)        
Stock-based compensation expense related to options granted   1,224,000,000     $ 1,397,000,000        
Unamortized employee stock-based compensation   1,600,000     $ 1,600,000        
Unamortized employee stock-based compensation expected to recognized over remaining estimated vesting period         1 year 7 months 24 days        
Total fair value of shares vested   1,100,000              
Aggregate intrinsic value   800,000              
Restricted stock units | Maximum                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Stock based awards vesting period         2 years        
Restricted Stock Awards (RSAs)                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Unamortized employee stock-based compensation   1,600,000     $ 1,600,000        
Unamortized employee stock-based compensation expected to recognized over remaining estimated vesting period         3 years 2 months 23 days        
Restricted Stock Awards (RSAs) | Novosteo                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Common stock reserved for issuance             0.0911    
Employees And Non Employees                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Stock-based compensation expense related to options granted   3,439,000     $ 10,462,000        
Employees And Non Employees | Novosteo                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Stock-based compensation expense related to options granted   87,000,000     87,000,000        
Employees And Non Employees | Restricted Stock Awards (RSAs)                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Stock-based compensation expense related to options granted   $ 76,000,000     $ 76,000,000        
2019 Plan                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Maximum aggregate number of shares that may be issued under the plan   8,591,030     8,591,030        
Increase in number of shares available for issuance as proportion of shares of common stock   2,146,354     2,146,354        
Percentage of common stock outstanding         4.00%        
Common stock reserved for issuance   1,596,650     1,596,650        
2019 Plan | Novosteo                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Maximum aggregate number of shares that may be issued under the plan             544,985    
Common stock reserved for issuance   37,337     37,337        
2019 Plan | Performance Stock Options                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Number of Shares, Surrendered         (675,000)        
Unvested PSOs cancelled                 675,000
2019 ESPP                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Increase in number of shares available for issuance as proportion of shares of common stock   536,589     536,589        
Percentage of common stock outstanding         1.00%        
Common stock reserved for issuance   1,133,165     1,133,165        
Maximum period for common stock shares reserved for future issuance         10 years        
2022 Inducement Plan                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Increase in number of shares available for issuance as proportion of shares of common stock               4,000,000  
Common stock reserved for issuance   255,745     255,745        
Unamortized employee stock-based compensation   $ 8,300,000     $ 8,300,000        
Unamortized employee stock-based compensation expected to recognized over remaining estimated vesting period         3 years 10 months 24 days        
2022 Inducement Plan | Employees And Non Employees                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Stock-based compensation expense related to options granted   $ 226,000,000     $ 226,000,000